As part of the ongoing growth and development of its business, Charnwood Molecular has secured the services of Dr. David Lathbury.
Dr Lathbury has over 25 years of industrial experience in the fine chemical, agrochemical, and pharmaceutical fields. Over the last 20 years he has worked in the pharmaceutical arena at SmithKline Beecham, and at AstraZeneca, where he was Head of Process Chemistry. Most recently he was Vice President of Chemical Development at Albany Molecular Research in Syracuse, New York.
During his extensive career, David has worked on four marketed drugs, including process re-development activities on “Seroquel” and “Paxil”. During his time at AstraZeneca, his team was responsible for the chemical development of “Iressa” and “Crestor”. He is author or co-author on 30 publications and patents.
David is a Fellow of the Royal Society of Chemistry and is a visiting Professor at Bristol University. He is also a member of the EPSRC strategic advisory team and was Chair of the 2012 Gordon Research Conference on Heterocyclic Compounds.
David will now work with a team of experienced scientists at Charnwood Molecular to build a unique and sector-leading Chemical and Process Development service to add to Charnwood’s existing Contract Research activities in Medicinal Chemistry, Custom Synthesis and Contract Research.
For more information, please contact Dr. Robin Wilkes, Director of Business Development (Medicinal Chemistry) at firstname.lastname@example.org